Edwards Lifesciences (EW) Gross Profit (2009 - 2026)

Edwards Lifesciences has reported Gross Profit for 18 years, with the latest figure at $1.3 billion in Q2 2026.

• On a quarterly basis, Gross Profit rose 13.54% year-over-year to $1.3 billion in Q2 2026; TTM through Jun 2026 was $5.1 billion, a 13.05% increase from a year earlier, with the FY2025 full-year figure at $4.7 billion, up 9.52% from the prior year.
• Gross Profit was $1.3 billion for Q2 2026 at Edwards Lifesciences, up from $1.3 billion in the prior quarter.
• The five-year high for Gross Profit was $1.3 billion in Q2 2026, with the low at $528.7 million in Q4 2022.
• Average Gross Profit over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Gross Profit sank 48.18% in 2022, then jumped 92.06% in 2023.
• Over 5 years, Gross Profit stood at $528.7 million in 2022, then soared by 92.06% to $1.0 billion in 2023, then rose by 7.7% to $1.1 billion in 2024, then grew by 12.16% to $1.2 billion in 2025, then advanced by 9.95% to $1.3 billion in 2026.
• The last three Gross Profit figures came in at $1.3 billion (Q2 2026), $1.3 billion (Q1 2026), and $1.2 billion (Q4 2025), per Business Quant data.